Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

2.

Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease.

Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, Mintun MA, Holtzman DM, Morris JC.

Neurology. 2011 Feb 8;76(6):501-10. doi: 10.1212/WNL.0b013e31820af900. Epub 2011 Jan 12.

3.

Independent practice associations: risk contracting, financial controls and processes.

Aeschleman M, Koch A.

Med Group Manage J. 1993 Jul-Aug;40(4):70, 72, 74 passim.

PMID:
10127371

Supplemental Content

Loading ...
Support Center